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BACKGROUND. A review of clinicopathologic features and outcome in women with
carcinosarcoma of the ovary (also known as malignant mixed mesodermal tumor
[MMMT]) compared with a group of women with serous adenocarcinoma (SAC) of
the ovary was conducted.
METHODS. Between 1984 and 2002, 1568 patients with epithelial ovarian carcinoma
and 70 patients with ovarian carcinosarcoma underwent treatment at the Edin-
burgh Cancer Centre. Analysis was performed on 65 patients with MMMT, and 746
patients with SAC were selected as a group for comparison. Baseline variables were
recorded prospectively and response to chemotherapy and progression-free and
cause-speciﬁc survival between the groups were compared.
RESULTS. Patients with carcinosarcoma had a mean age of 66.6 years, which is
signiﬁcantly older than those with SAC (62.0 years) (P  0.001). The objective
response rate to platinum-based chemotherapy was found to be signiﬁcantly lower
in patients with carcinosarcoma (25% vs. 60%; P  0.02). Cause-speciﬁc survival in
the carcinosarcoma group was poor and signiﬁcantly shorter than that observed in
the SAC group (median survival of 8.2 months vs. 20.7 months; P  0.0001).
Progression-free survival in patients with carcinosarcoma also was found to be
signiﬁcantly shorter compared with patients with SAC (median progression-free
survival of 6.4 months vs. 12.1 months; P  0.001). Achieving optimal debulking at
the time of initial surgery was found to be a highly signiﬁcant factor in patients
with carcinosarcoma with regard to determining outcome (median survival of 14.8
months for patients with optimally debulked International Federation of Gynecol-
ogy and Obstetrics Stage III disease vs. 3.1 months for patients with suboptimally/
nondebulked Stage III disease; P  0.001).
CONCLUSIONS. Ovarian carcinosarcoma is a distinct entity with a poor prognosis.
Patients with carcinosarcoma differ from those with SAC with regard to having an
older mean age of onset, an inferior response to platinum-based chemotherapy,
and worse progression-free and cause-speciﬁc survival. The extent of beneﬁt from
chemotherapy is unclear. Cancer 2004;100:2148–53.
© 2004 American Cancer Society.
KEYWORDS: carcinosarcoma, malignant mixed mesodermal tumor (MMMT), ovary,
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Carcinosarcomas (also termed malignant mixed mesodermal tu-mors [MMMTs], sarcomatoid carcinomas, or malignant mixed
mu¨ullerian tumors) are relatively rare gynecologic tumors that occur
throughout the female genital tract, most commonly in the uterus.
Ovarian carcinosarcomas are reported to represent  2% of ovarian
malignancies.1
Histologically, carcinosarcomas are epithelial tumors that are
comprised of both a carcinomatous and sarcomatous component.
They are subclassiﬁed as “heterologous” or “homologous” according
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to the presence or absence of a stromal component
containing mesenchymal tissue not normally found at
the primary tumor site. Previously, it was believed that
heterologous carcinosarcomas carried a worse prog-
nosis, but recent evidence suggests that this histologic
feature does not signiﬁcantly alter prognosis.2
The pathogenesis of carcinosarcomas remains un-
der debate but immunologic studies and molecular
studies have suggested that both malignant elements
(carcinoma and sarcoma) originate from a common
epithelial stem cell (the combination theory) as op-
posed to two distinct malignant cell populations of
different origin (the collision theory).1,3–14
To our knowledge there are few studies published
to date regarding ovarian carcinosarcomas involving
large numbers of patients and the behavior and man-
agement of these tumors remains controversial. Gen-
erally, they present in a manner similar to carcinomas
of the ovary with abdominal distension, pain, nausea,
emesis, and weight loss. In some series, the pattern of
spread was found to be similar to epithelial ovarian
carcinoma, with early serosal and peritoneal dissemi-
nation.1 Despite relatively high response rates to che-
motherapy,15–17 patients with carcinosarcoma often
quickly develop a recurrence and have a poor prog-
nosis. Long-term survival is an unlikely prospect but is
determined mainly by curative primary surgery in ear-
ly-stage tumors. Although chemotherapy is commonly
utilized in the setting of advanced disease, to our
knowledge its role in the adjuvant setting has not been
clariﬁed in the context of randomized controlled trials.
In the current study, we report a review of pro-
spectively recorded data concerning the clinical char-
acteristics, management, and outcome of 65 patients
with MMMT compared with a group of 746 patients
with serous adenocarcinoma (SAC). To the best of our
knowledge, this is the largest carcinosarcoma cohort
reported to date.
MATERIALS AND METHODS
Between 1984 and 2002, a total of 1568 patients with
epithelial ovarian carcinoma and 70 patients with
ovarian carcinosarcoma underwent treatment at the
Edinburgh Cancer Centre, Western General Hospital,
Edinburgh, U.K. (Table 1). Baseline variables were re-
corded prospectively, including age, World Health Or-
ganization (WHO) performance status, CA 125 level,
tumor stage, and histologic subtype. In all cases, a
histologic diagnosis of carcinosarcoma was conﬁrmed
by review of sections by a gynecologic pathologist. Of
this group of 70 patients, 5 were excluded due to prior
malignancy. A total of 746 patients with SAC were
selected as a control group for a comparison of prog-
nosis (patients with a prior malignancy again were
excluded).
Using the International Federation of Gynecology
and Obstetrics (FIGO) classiﬁcation, disease was
staged by surgical ﬁndings at the time of diagnosis and
by computed tomography (CT) scan. All surgery was
performed according to agreed-upon U.K. standards
by either a specialist in gynecologic oncology or a
gynecologist with a special interest in gynecologic on-
cology.
Chemotherapy was administered to 43 of 65 pa-
tients with carcinosarcoma (Table 2). The platinum-
containing regimens included carboplatin (21 pa-
tients), cisplatin (11 patients), a combination of
cisplatin and doxorubicin (3 patients), a combination
of cisplatin and ifosfamide (1 patient), and a combi-
nation of carboplatin and altretamine (1 patient). The
nonplatinum-containing regimens included doxoru-
bicin and ifosfamide (one patient), chlorambucil
(three patients), etoposide (one patient), and treosul-
TABLE 1
Characteristics of Patients with MMMT and Patients with SACa
MMMT SAC
Total no. of patients 65 746
Mean age (yrs) (SD) 66.6 (9.2) 62.0 (11.4) P  0.001
FIGO Stage I 6 (9%) 68 (9%)
Stage II 6 (9%) 57 (8%)
Stage III 41 (63%) 471 (63%)
Stage IV 11 (17%) 142 (19%)
Unknown stage 1 (2%) 8 (1%)
Optimally debulked ( 2 cm) 28 (43%) 305 (41%)
Suboptimally debulked ( 2 cm) 27 (42%) 377 (51%)
Unknown debulking status 10 (15%) 64 (9%)
Homologous tumor 18 (28%)
Heterologous tumor 36 (55%)
Unknown 11 (17%)
MMMT: malignant mixed mesodermal tumor; SAC: serous adenocarcinoma; SD: standard deviation;
FIGO: International Federation of Obstetrics and Gynecology.
a Differences were not signiﬁcant except when noted.
TABLE 2
Chemotherapy Regimens used
MMMT SAC
Platinum-containing regimens 37 (57%) 545 (73%)
Single-agent platinum 32 (49%) 329 (44%)
Platinum plus taxane 0 (0%) 87 (12%)
Platinum plus other drugs 5 (8%) 129 (17%)
Nonplatinum 6 (9%) 88 (12%)
No chemotherapy 22 (34%) 113 (15%)
Total 65 746
MMMT: malignant mixed mesodermal tumor; SAC: serous adenocarcinoma.
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phan (one patient). The remaining patients did not
receive chemotherapy because of a number of factors
including poor performance status/comorbidity (12
patients), advanced age (4 patients), patient refusal (3
patients), and early-stage disease (1 patient). For two
patients, the reason for not receiving chemotherapy
was unknown.
For patients with measurable disease, response to
chemotherapy was evaluated by CT according to WHO
response criteria.18 A complete response (CR) was de-
ﬁned as the complete disappearance of all clinically
detectable disease for at least 4 weeks. A partial re-
sponse (PR) was deﬁned as a  50% decrease in the
sum of the products of the largest perpendicular di-
mensions of all measurable or evaluable lesions for at
least 4 weeks without an increase in the size of any
known lesion or the appearance of a new lesion. No
change was deﬁned as a  50% decrease and  25%
increase in the sum of measurable or evaluable lesions
for at least 6 weeks. Progressive disease was deﬁned as
the appearance of a new lesion or a  25% increase in
the sum of measurable or evaluable lesions.
For patients without measurable disease on CT
scan, response to chemotherapy was calculated ac-
cording to CA 125 response using the criteria of Rustin
et al.19,20
Patient survival distribution was calculated using
the Kaplan–Meier method. The survival analysis was
performed based on disease-speciﬁc survival because
11 patients (10 patients with SAC and 1 with carcino-
sarcoma) died of causes other than ovarian carcinoma
and were free of disease at the time of death. These
ﬁndings are very similar to those obtained by all-cause
mortality analysis. The signiﬁcance of the survival dis-
tribution in each group was tested with the log-rank
test.
RESULTS
Patient Characteristics
Patient characteristics are shown in Table 1. The mean
age of patients with carcinosarcoma (66.6 years) was
signiﬁcantly higher than that of patients with SAC
(62.0 years) (P  0.001). Of those patients for whom a
baseline performance status was recorded (42% of
those with carcinosarcoma and 61% of those with
SAC), 30% of patients with carcinosarcoma had a
WHO performance status of 3–4 compared with 8% of
those with SAC (P  0.001). Of the 65 patients with
carcinosarcoma, 6 patients (9%) had Stage I disease
[T1N0M0], 6 patients (9%) had Stage II disease
[T2N0M0], 41 patients (63%) had Stage III disease
[T3N0M0 or any T,N1], and 11 patients (17%) had
Stage IV disease [any T any N, M1] according to the
FIGO classiﬁcation. The stage distribution was similar
between patients with carcinosarcoma and those with
SAC. A lower proportion of patients with carcinosar-
coma were found to have ascites at the time of pre-
sentation (67%) compared with patients with SAC
(78%) (P  0.05). Approximately 74% of patients with
carcinosarcoma had an elevated baseline CA 125 level
after surgery compared with 85% of patients with SAC
(P  0.095). Using the reverse Kaplan–Meier method,
the overall median duration of follow-up was 84
months (42 months for patients with MMMT and 86
months for patients with SAC [range, 1–228 months]).
Clinical Outcome
Fourteen patients with Stage III/IV carcinosarcoma
(27%) had radiologically measurable disease after ini-
tial surgery, 12 of whom received platinum-based che-
motherapy. One of these patients achieved a CR (8%)
and 2 patients achieved a PR (17%) (Table 3); thus, the
overall objective response rate was 25%. Progressive
disease was documented in 7 patients (58%) and no
change was documented in 2 patients. Using CA 125
as a method of assessing response, 7 of 17 patients
(41%) achieved a response to platinum-based chemo-
therapy according to criteria of Rustin et al.19,20 There
were 10 patients who had evaluable disease based on
Rustin et al.’s CA 125 criteria who did not have radio-
logically measurable disease. Two patients with evalu-
able disease were treated with nonplatinum-based
chemotherapy; neither achieved a response.
Three hundred two patients with Stage III/IV SAC
(49%) were found to have measurable disease after
surgery. Of the 258 patients who received platinum-
based chemotherapy, 54 patients (21%) achieved a CR
and 101 (39%) achieved a PR to platinum-based che-
motherapy; thus, the overall objective response rate
was 60%. Progressive disease was documented in 61
TABLE 3
Response to Platinum-Based Chemotherapy
No. of
patients
Response
Response
rate (%)CR PR NC PD
Rad MMMT 12 1 2 2 7 25
SAC 258 54 101 42 61 60 P  0.02
Response No response
CA 125 MMMT 17 7 10 41
Serous 331 207 124 63 P  0.08
CR: complete response; PR: partial response; NC: no change; PD: progressive disease; Rad: radiologic
response; MMMT: malignant mixed mesodermal tumor; SAC: serous adenocarcinoma; CA 125: CA 125
response.
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patients (24%) and no change was documented in 42
patients (16%). The CA 125 response rate was 63%.
Recurrence of carcinosarcoma occurred in 50% of
Stage I patients (3 of 6 patients), 100% of Stage II
patients (6 of 6 patients), 90% of Stage III patients (37
of 41 patients), and 100% of Stage IV patients (11 of 11
patients). The median time to disease recurrence was
6.4 months. The median time to recurrence in patients
with SAC was 12.1 months.
In those patients with carcinosarcoma, the me-
dian survival time was 75.5 months in patients with
Stage I disease, 5.1 months in patients with Stage II
disease, 8.5 months in patients with Stage III disease,
and 5.5 months in patients with Stage IV disease. In
the patients with SAC, the median survival time was
164.2 months in patients with Stage I disease, 45.7
months in patients with Stage II disease, 18.5 months
in patients with Stage III disease, and 15.0 months in
patients with Stage IV disease.
Overall, patients with ovarian carcinosarcoma had
a median survival of 8.2 months, a 2-year survival rate
of 23% and a 5-year survival rate of 15% (Table 4) (Fig.
1). In the patients with SAC, the overall median sur-
vival was 20.7 months with a 2-year survival rate of
44% and a 5-year survival rate of 20%. The difference
in overall survival between the groups was found to be
highly statistically signiﬁcant (P  0.0001)
Table 5 and Figure 2 show the estimated survival
rates in patients with Stage III carcinosarcoma when
such patients are divided into 2 groups: a group with
 2 cm residual disease after initial surgery (“opti-
mally debulked”) and a group with  2 cm residual
tumor (‘suboptimally/nondebulked’). The 19 patients
with Stage III carcinosarcoma who were in the “opti-
mally debulked” group had a median survival of 14.8
months with a 2-year survival rate of 39%. The 17
patients in the “nondebulked/ suboptimally de-
bulked” group had a signiﬁcantly lower median sur-
vival of 3.1 months (P  0.001) and a 2-year survival
rate of 0%.
FIGURE 1. Kaplan–Meier estimated survival for patients with serous ade-
nocarcinoma (bold line) and malignant mixed mesodermal tumor (MMMT)
(dotted line).
FIGURE 2. Kaplan–Meier estimated survival for patients with International
Federation of Gynecology and Obstetrics Stage III malignant mixed mesodermal
tumor with optimally debulked ( 2 cm) (bold line) and suboptimally debulked/
nondebulked ( 2 cm) (dotted line) disease.
TABLE 4
Estimated Survival Rate for MMMT versus SAC by Stage of Disease
MMMT SAC
FIGO
Stage
No. of
patients
2-yr
survival
5-yr
survival
No. of
patients
2-yr
survival
5-yr
survival
I 6 83% 83% 68 94% 76%
II 6 0 0 57 75% 32%
III 41 22% 0 471 39% 15%
IV 11 0 0 142 23% 3%
All stages 65 23% 15% 746 44% 20% P  0.0001
MMMT: malignant mixed mesodermal tumor; SAC: serous adenocarcinoma; FIGO: International Fed-
eration of Gynecology and Obstetrics.
TABLE 5
Estimated Survival Rate of Patients with FIGO Stage III Disease Based
on Size of Residual Tumor
Initial surgery
MMMT SAC
2-yr
survival
5-yr
survival
2-yr
survival
5-yr
survival
 2 cm residual tumor 39% 0 61% 33%
 2 cm residual tumor 0 0 26% 4%
FIGO: International Federation of Gynecology and Obstetrics; MMMT: malignant mixed mesodermal
tumor; SAC: serous adeno- carcinoma.
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DISCUSSION
It has been suggested from previous studies that ovar-
ian carcinosarcoma is a relatively rare clinicopatho-
logic entity that has a tendency to affect an elderly
population and is associated with poor prognosis. In
the current series, we found that carcinosarcomas rep-
resented 4% of the total number of epithelial ovarian
carcinomas, which to our knowledge is a higher pro-
portion than previously described.1 It was conﬁrmed
that carcinosarcoma tends to affect a more elderly
population than does SAC, with the mean age of pa-
tients with carcinosarcoma (66.6 years) being signiﬁ-
cantly older than that of patients with SAC (62.0
years). Patients with carcinosarcoma were more likely
to have a poor performance status, with 30% of pa-
tients having a WHO performance status of 3–4 at
baseline compared with only 8% of patients with SAC.
Although this difference is statistically signiﬁcant, it
should be interpreted with caution because only 42%
of patients with carcinosarcoma had a baseline per-
formance status recorded (compared with 61% of pa-
tients with SAC). There was a similar stage distribution
in the carcinosarcoma and SAC groups, with the ma-
jority of patients having advanced disease (Stage III/
IV) at the time of presentation (80% of patients with
carcinosarcoma vs. 82% with SAC). There appeared to
be a higher proportion of patients with carcinosar-
coma who had a negative CA 125 level (i.e., within the
reference range) at baseline (26%) compared with pa-
tients with SAC (15%), although this difference was not
found to be statistically signiﬁcant.
To our knowledge, there is no well established
consensus regarding which patients with carcinosar-
coma should receive chemotherapy and which che-
motherapy regimen(s) should be regarded as opti-
mum. This uncertainty may in part be reﬂected in the
variety of different chemotherapy regimens used in
the current series and the relatively higher proportion
of patients with carcinosarcoma compared with SAC
who did not receive chemotherapy as part of their
management (34% vs. 15%). The response rate to plat-
inum-based chemotherapy for patients with carcino-
sarcoma was found to be 25%, a rate that is inferior to
the previously published data of between 33–47%.15–17
A signiﬁcantly inferior response rate of carcinosar-
coma to platinum-based chemotherapy compared
with SAC was conﬁrmed (25% vs. 60%; P  0.02). The
published data concerning response to chemotherapy
in ovarian carcinosarcoma is comprised of a number
of relatively small series collected over many years
using a number of different chemotherapy regimens,
the majority of which were platinum-based. In what to
our knowledge is the largest series published to date,
which was reported by Harris et al.15 and was com-
prised of 40 patients, the majority of patients received
platinum-based chemotherapy. The response rate was
40% with an overall median survival of 8.7 months.
Prendeville et al.16 reported a series of 20 patients, 15
of whom received chemotherapy. The regimens used
were predominantly based on cyclophosphamide,
with the minority of patients receiving platinum. The
response rate was 47% with a median survival of 14
months. Chang et al.17 reported a series of 37 patients,
the majority of whom received platinum-based che-
motherapy, either as a single agent or in a variety of
combinations. The response rate was 33% with a me-
dian survival of 8 months.
In the current study, only 18 of 65 patients with
carcinosarcoma had CA 125 measurements that al-
lowed a response to be assessed according to the
criteria established by Rustin et al.19,20 Of these 18
patients, 5 were found to have a CA 125 response who
did not have radiologically evaluable disease; 1 patient
achieved a CA 125 response despite being found to
have stable disease on CT scan. The remainder of the
CA 125 results demonstrated a trend that largely mir-
rored those observed on radiologic assessment. To our
knowledge, assessing response according to CA 125
using the criteria of Rustin et al.19,20 has not been
validated for use in carcinosarcoma but does appear
to provide a useful marker of response in some pa-
tients who do not have radiologically measurable dis-
ease and therefore may provide useful information in
these patients to augment that gained from clinical
assessment.
The overall median survival for patients with car-
cinosarcoma was found to be poor (8.2 months) and
was signiﬁcantly shorter than the median survival for
patients with SAC (20.7 months). Survival did not ap-
pear to be inﬂuenced by the presence of heterologous
elements observed on pathology. A statistically signif-
icant survival beneﬁt for those patients with Stage III
carcinosarcoma in whom optimal debulking was
achieved at surgery was conﬁrmed. This emphasizes
the importance of an aggressive surgical approach in
patients with Stage III carcinosarcoma.
The results of the current study conﬁrm that car-
cinosarcomas differ from SACs with regard to their age
at onset and response to platinum-based chemother-
apy. A more aggressive clinical course and a worse
survival than SACs is conﬁrmed. Optimal debulking at
the time of surgery appears to be of prognostic signif-
icance but to our knowledge the optimal use of che-
motherapy has yet to be identiﬁed fully.
These results emphasize the need to recognize
ovarian carcinosarcoma as a distinct clinicopathologic
entity that requires a different strategy in its manage-
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ment compared with SAC that takes into account the
older population, their often poor performance status,
and their relative resistance to platinum-based che-
motherapy. To our knowledge, no randomized evi-
dence exists for a survival beneﬁt from chemotherapy
of any kind for ovarian carcinosarcoma. Therefore,
there is a clear need for randomized controlled trials
to explore the optimum role of chemotherapy in ovar-
ian carcinosarcoma.
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